Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EC Seeks To Provide More Drug Information But Not Through DTC Ads

Executive Summary

The European Commission intends to propose regulatory changes aimed at ensuring that patients have greater access to non-biased information on medications

You may also be interested in...



PhRMA Weighs In On European Consumer Drug Information Proposal

Supporting a proposed European policy change permitting manufacturers to provide more drug information to the public, the Pharmaceutical Research and Manufacturers of America suggests that permissible information could include ongoing clinical research and disease management data not contained in approved product summaries

PhRMA Weighs In On European Consumer Drug Information Proposal

Supporting a proposed European policy change permitting manufacturers to provide more drug information to the public, the Pharmaceutical Research and Manufacturers of America suggests that permissible information could include ongoing clinical research and disease management data not contained in approved product summaries

FDA’s DTC Pre-Review Authority Will Face Court Challenge, Lawyers Predict

FDA authority to require pre-review of direct-to-consumer television ads "likely will be tested at some point in the courts," David Ogden of WilmerHale predicted during an Oct. 31 audioconference on the FDA Amendments Act

Related Content

UsernamePublicRestriction

Register

PS049147

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel